Arvinas’ ARV-110 Receives the US FDA’s Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer in Men

 Arvinas’ ARV-110 Receives the US FDA’s Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer in Men

Arvinas’ ARV-110 Receives the US FDA’s Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer in Men

Shots:

  • Arvinas’ ARV-110 is an orally available PROTAC protein degrader used for targeting androgen receptor (AR) protein and is currently evaluated in P-I for its safety, tolerability, and PK in men with 2L+ mCRPC
  • In Q1’19, Arvinas initiated its P-I study of ARV-110 for mCRPC with its preliminary clinical data sharing in H2’19 and expected full disclosure of study in H1’20
  • Arvinas’ PROTAC protein degraders (Proteolysis-Targeting Chimera) are used for harnessing body’s immune system to degrade disease-causing proteins with the help of E3 ligase for tagging the protein with ubiquitin, further leading to its degradation through proteasome

Click here to read full press release/ article | Ref: Arvinas | Image: The Pharma Letter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post